XML 31 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible assets
12 Months Ended
Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]  
Intangible assets

6.

Intangible assets

Intangible assets are recorded at cost, or when acquired as a part of a business combination, at estimated fair value. These assets are amortized on a straight-line basis over the useful lives of the assets.

 

 

 

 

 

December 31,

 

(U.S. Dollars, in thousands)

 

Weighted Average Amortization Period

 

2019

 

 

2018

 

Cost

 

 

 

 

 

 

 

 

 

 

Patents

 

10 years

 

$

42,034

 

 

$

39,085

 

Developed technology

 

10 years

 

 

39,200

 

 

 

12,400

 

IPR&D

 

Indefinite

 

 

 

 

 

26,800

 

Customer relationships

 

9 years

 

 

7,430

 

 

 

 

License and other

 

7 years

 

 

15,960

 

 

 

14,654

 

Trademarks—finite lived

 

10 years

 

 

942

 

 

 

840

 

 

 

9 years

 

 

105,566

 

 

 

93,779

 

Accumulated amortization

 

 

 

 

 

 

 

 

 

 

Patents

 

 

 

$

(38,246

)

 

$

(35,016

)

Developed technology

 

 

 

 

(4,523

)

 

 

(827

)

Customer relationships

 

 

 

 

(535

)

 

 

 

License and other

 

 

 

 

(7,701

)

 

 

(5,744

)

Trademarks—finite lived

 

 

 

 

(422

)

 

 

(295

)

 

 

 

 

 

(51,427

)

 

 

(41,882

)

Patents and other intangible assets, net

 

 

 

$

54,139

 

 

$

51,897

 

 

 

Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they are not amortized but tested for impairment. Impairment testing is performed at least annually or when a triggering event occurs that could indicate a potential impairment. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets are deemed finite-lived and are amortized over a period that best reflects the economic benefits provided by these assets. On February 6, 2019, the Company obtained FDA approval of the M6-C artificial cervical disc for patients suffering from cervical disease degeneration. Following FDA approval, the Company transferred $26.8 million from IPR&D to developed technology, and began amortization over 10 years.

 

Amortization expense for intangible assets was $7.0 million, $2.7 million and $1.8 million for the years ended December 31, 2019, December 31, 2018 and 2017, respectively. Future amortization expense for intangible assets is estimated as follows:

 

(U.S. Dollars, in thousands)

 

Amortization

 

2020

 

$

7,420

 

2021

 

 

7,317

 

2022

 

 

7,337

 

2023

 

 

6,668

 

2024

 

 

5,799

 

Thereafter

 

 

19,598

 

Total

 

$

54,139